Heavyweight news! Yiduqiao Pharmaceutical (00512.HK) releases global innovative drug STC3141 Phase II clinical data in China, bringing breakthrough progress in the treatment of sepsis.

Recently, the Hong Kong-listed technology innovative international pharmaceutical company Uni-Bio Science Group Limited (00512.HK) announced a major breakthrough. The company's self-developed global innovative drug, STC3141, has successfully reached its clinical endpoints in a Phase II clinical study conducted in China for the treatment of sepsis. The trial results confirm the effectiveness and safety of STC3141 in the treatment of sepsis, positioning the company at the forefront of global research in the field of sepsis.